BioSpace News Archive

Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced the appointment of Michael Retterath as chief strategy officer.

Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020. The pre-recorded fireside chat will be accessible beginning November

Weill Cornell Medicine’s Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque psoriasis

Q3 2020 Adjusted Total Revenue - $16.7 million - - Q3 2020 Adjusted EBITDA - $6.6 million - - Blexten Canadian Prescriptions Increased 30% Year-Over-Year - - Cambia Canadian Prescriptions Increased 13% Year-Over-Year - Nuvo to Host Conference Call/Audio Webcast November 16 at 8:30 a.m. ET

— Milestone Achievement Reflects First Investigational Candidate to Emerge Under Multi-Target Collaboration and Triggers $10 Million Payment to Dicerna — – Lilly Targeting Initiation of Phase 1 Clinical Trial of LY3561774 by Year-End 2020 –

Data Presentations Show Treatment With Up to Four Monthly Doses of RG6346 Resulted in Substantial and Durable Reductions in HBsAg Levels Lasting Up to One Year After Last Dose

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies London Healthcare Conference on Thursday, November 19, 2020, at 12:00 p.m. ET. A live webcast of the event will be available on the “Events & Presentations” page

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX:VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that it has been invited to present at Stifel Virtual Healthcare Conference, being held on Wednesday, November 18, 2020.

Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals’ innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with v

▪ Data from the monkey challenge study published in Nature Communications showed a single dose of neutralizing antibody ABP 300 blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting ▪ Safety demonstrated in non-human primates ▪ ABP 300 showed the potential to neutralize eight SARS-CoV-2 strains with reported high-frequency mutations